Acne vulgaris is one of the most common inflammatory skin conditions worldwide, affecting the pilosebaceous unit through a combination of excessive sebum production, abnormal follicular keratinisation, microbial imbalance—particularly involving Cutibacterium acnes (formerly Propionibacterium acnes)—and immune-mediated inflammation. Because acne develops through multiple biological pathways, effective management often requires approaches that target excess oil production, inflammation and skin barrier function simultaneously.

In recent years, hemp-derived cannabidiol (CBD) has attracted growing interest in dermatology due to its anti-inflammatory, sebostatic and immunomodulatory properties. Unlike ingredients that act on a single pathway, CBD has been shown to influence several biological processes associated with acne development, making it a promising candidate for topical skincare and cosmeceutical applications.

A recently published systematic review in the journal Molecules examined the current evidence surrounding hemp-derived cannabinoids—particularly CBD—and their potential role in acne management. Following the PRISMA 2020 reporting guidelines, researchers reviewed preclinical and clinical studies published between 2010 and 2024, evaluating CBD's mechanisms of action, clinical efficacy, formulation considerations and sustainability within the hemp supply chain.

The review concludes that while current evidence remains preliminary, CBD demonstrates considerable potential as an adjunctive skincare ingredient for mild-to-moderate inflammatory acne.


How CBD May Help Improve Acne

Acne is driven by several interconnected mechanisms, including excessive sebum production, chronic inflammation and altered keratinocyte activity. According to the review, CBD appears capable of influencing each of these processes.

Regulation of Sebum Production

Overproduction of sebum is one of the primary contributors to acne formation.

Laboratory studies using human sebocytes have shown that CBD can reduce excessive lipid synthesis while inhibiting abnormal sebocyte proliferation. By helping normalise sebum production, CBD may reduce one of the key biological drivers behind clogged pores and inflammatory lesions.

Further experimental research using human skin organ cultures suggests that CBD modulates the TRPV4/A2A signalling pathway, reducing lipogenesis while simultaneously suppressing inflammatory signalling pathways such as NF-κB and MAPK. This dual activity may explain why CBD has attracted attention as a multi-target skincare ingredient.

Anti-Inflammatory Activity

Persistent inflammation plays a central role in acne progression.

The review found that CBD may help regulate several inflammatory pathways by reducing the production of pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8). These inflammatory mediators are closely associated with redness, swelling and the development of inflammatory acne lesions.

Experimental evidence suggests that CBD exerts these effects through interactions with cannabinoid receptor CB2 and members of the transient receptor potential vanilloid (TRPV) family, contributing to a reduction in inflammatory responses within the skin.

Supporting Skin Barrier Function

Beyond its effects on sebum and inflammation, CBD may also influence keratinocyte behaviour.

Studies included in the review indicate that CBD can regulate keratinocyte responses to Cutibacterium acnes-related inflammatory stimuli, potentially helping maintain skin barrier integrity while limiting excessive inflammatory signalling.

Together, these mechanisms suggest that CBD targets multiple biological pathways involved in acne development rather than simply masking symptoms.


What Do Clinical Studies Show?

While laboratory findings are encouraging, clinical evidence remains relatively limited.

Across the studies reviewed, topical formulations containing CBD were associated with reductions in inflammatory lesion counts, facial redness and sebum production following regular application.

One 12-week non-randomised clinical study reported an average reduction of approximately 40% in acne lesions after topical CBD treatment, alongside improvements in overall skin appearance.

However, researchers caution that many of the formulations investigated contained additional active ingredients, making it difficult to attribute the observed benefits exclusively to CBD. Furthermore, most available clinical trials involve relatively small sample sizes and employ varying outcome measures, highlighting the need for larger, well-designed randomised controlled trials.


Safety Profile

Current evidence suggests that topical CBD is generally well tolerated.

Across the clinical studies included in the review, fewer than 10% of participants reported mild local skin irritation, while no serious adverse events were documented. These findings indicate a favourable short-term safety profile for topical CBD formulations.

Nevertheless, researchers emphasise that long-term safety data remain limited, and additional studies involving larger populations and longer follow-up periods are required to better understand its long-term tolerability.


Current Limitations

Although the review highlights promising findings, the authors stress that existing evidence should be interpreted cautiously.

Significant differences exist between studies regarding CBD concentration, formulation, source material and treatment duration, making direct comparisons challenging.

In addition, many clinical studies investigated multi-ingredient formulations rather than purified CBD alone. As a result, the independent contribution of CBD cannot yet be fully established.

The review also notes the absence of standardised acne severity assessments and patient-reported outcome measures across several studies, limiting the overall strength of current evidence.

Importantly, there is currently insufficient evidence to confirm that CBD possesses clinically meaningful direct antimicrobial activity against Cutibacterium acnes, nor is there adequate evidence demonstrating sustained long-term clinical benefit.


How Does CBD Compare with Conventional Acne Treatments?

Conventional acne management typically includes topical retinoids, benzoyl peroxide, azelaic acid and topical or oral antibiotics, with isotretinoin reserved for more severe cases.

While these therapies are supported by robust clinical evidence, they may also be associated with skin irritation, dryness, photosensitivity and, in the case of prolonged antibiotic use, antimicrobial resistance.

According to the review, hemp-derived CBD offers a different approach by targeting multiple biological pathways involved in acne development while demonstrating good short-term skin tolerability. However, researchers emphasise that CBD should currently be regarded as a complementary skincare ingredient rather than a replacement for evidence-based medical treatments.


Looking Ahead

The authors conclude that hemp-derived CBD demonstrates biological plausibility and encouraging early clinical evidence as a supportive ingredient for mild-to-moderate inflammatory acne.

Future research should focus on large-scale, placebo-controlled randomised clinical trials using standardised CBD formulations and validated clinical endpoints. Establishing clearer regulatory standards and incorporating sustainability considerations into product development may also help support responsible innovation within the growing hemp-derived skincare sector.

While further evidence is still needed, current research suggests that CBD has the potential to become an increasingly valuable component of evidence-informed skincare strategies aimed at supporting healthy, balanced skin.